# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Flannery O'Connor (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML046-SYN
- Date: 2026-04-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Augusta Pemberton-Diallo, MD
- Calendar frame: modern shifted

## What we are working on

- Painful, swollen hands and knees, fevers, tiredness, and a rash on her face, for three months **S**
- Wants a plain, complete answer about what is wrong, told to her directly, and asks that it not be shared with anyone she has not named **S**
- Afraid of losing her writing mornings to illness or treatment **S**

## Your goals

- Establish the diagnosis within two weeks and hear it directly, in plain words. Target: 2026-04-22. Recorded outcome: Told directly at nine days that she has systemic lupus erythematosus, with the reasons and a written summary. **S**
- Renal response: urine protein-to-creatinine ratio halved by three months and below 0.5 g/g with stable kidney function by six to twelve months. Target: 2026-10-26. Recorded outcome: Ratio 1.8 at diagnosis, 0.9 at three months, 0.35 at six months, a complete response; creatinine 0.8 throughout. **S**
- Prednisone 5 mg a day or less by six months, with withdrawal considered later. Target: 2026-10-26. Recorded outcome: 5 mg a day at six months. **S**
- Write at least four mornings a week through treatment. Target: 2026-12-31. Recorded outcome: Writing five mornings a week by three months. **S**
- No unplanned pregnancy on mycophenolate; plan any pregnancy for a time of quiet disease on compatible medicines. Target: 2026-12-31. Recorded outcome: Intrauterine system in place; pregnancy planning discussed. **S**

## What we agreed to do

- Inflammatory arthritis with fever, rash, cytopenias, and an abnormal urine: blood count, chemistry, ESR and CRP, urine microscopy and protein-to-creatinine ratio today; ANA, anti-dsDNA, anti-Sm, complements, and antiphospholipid antibodies; no NSAIDs with protein in the urine. Guideline: 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71(9):1400-1412 (2019); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024) **S**
- Rheumatology consultation within ten days, to confirm the diagnosis, stage organ involvement, and plan treatment with her. Guideline: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023) **S**
- Disclosure: every result explained to her directly and in plain words, with a written copy; her health shared only with the people she names. Guideline: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023) **S**
- Sun protection: broad-spectrum sunscreen SPF 50 or higher, a wide-brimmed hat, and shade in the middle of the day. Guideline: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023) **S**
- Hydroxychloroquine 300 mg daily (5 mg/kg) for every patient with lupus, long term, with a baseline eye examination within the first year and yearly screening after five years. Guideline: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016;123(6):1386-1394 (2016) **S**
- Kidney biopsy for proteinuria above 0.5 g/g with an active sediment, to class the nephritis before treatment. Guideline: 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024) **S**
- Vaccinations before immunosuppression: PCV20 and recombinant zoster dose 1 now, zoster dose 2 after one to two months, seasonal influenza and COVID-19; no live vaccines on immunosuppression; hepatitis B, hepatitis C, and HIV screening. Guideline: 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2023;75(3):333-348 (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026) **S**
- Angiotensin receptor blocker (losartan) for proteinuria and blood pressure, target below 130/80 mmHg, with potassium and creatinine two to four weeks after starting. Guideline: 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease and hypertension monographs (2026) **S**
- Contraception before mycophenolate: highly effective method of her choice (levonorgestrel intrauterine system); pregnancy test before starting; pregnancy planning later for at least six months of quiet disease on pregnancy-compatible medicines. Guideline: 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res 2020;72(4):461-488 (2020); CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026) **S**
- Class III lupus nephritis: methylprednisolone 500 mg daily for three days, then prednisone 30 mg tapered to 5 mg a day or less by six months; mycophenolate mofetil 2 g a day with belimumab, continued for three to five years after a complete response; blood counts weekly for the first month, twice monthly for the next two, then monthly; urine protein-to-creatinine ratio, urine sediment, creatinine, anti-dsDNA, and complements every three months. Guideline: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); BENLYSTA (belimumab): prescribing information (subcutaneous dosing for lupus nephritis) (2026); CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026) **S**
- Bone protection on glucocorticoids: baseline DXA, vitamin D3 and calcium from food, weight-bearing exercise; report new hip, groin, or knee pain at once so avascular necrosis can be looked for with MRI. Guideline: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022) **S**
- Cardiovascular risk: blood pressure at every visit, lipids and HbA1c at three months on glucocorticoids, no smoking, activity, and a lower glucocorticoid dose. Guideline: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023) **S**
- Writing life: treatment visits and infusions booked in the afternoons, belimumab self-injected at home, fatigue managed with graded activity and sleep; her illness kept out of conversations about her work unless she chooses otherwise. Guideline: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023) **S**

## Follow-up

- 2026-04-13: Primary care visit for joint pain and swelling, fevers, fatigue, a facial rash, and protein in the urine in a writer of 25 **S**
- 2026-04-22: Diagnosis of systemic lupus erythematosus with the rheumatology consultation the same day; vaccinations before immunosuppression **S**
- 2026-04-29: Kidney biopsy result: class III lupus nephritis; start of pulse methylprednisolone, prednisone, mycophenolate, and belimumab **S**
- 2026-07-27: Three-month response assessment for lupus nephritis and glucocorticoid taper **S**
- 2026-10-05: Adult preventive visit **S**
- 2026-10-26: Six-month response assessment: complete renal response; prednisone 5 mg; pregnancy planning **S**

This teaching document does not replace care from a qualified clinician.
